Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03338348 |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 |
| completed |
| Phase 2 |
| 9 |
| University of UlmOTHER |
| 1 |
| Oct 28, 2020 |
| clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT00821249 | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00822770 | Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | completed | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02458235 | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | completed | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02763475 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | completed | Phase 2 | 7 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01910012 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia | completed | Phase 2 | 43 | Polaris GroupINDUSTRY | 2 | Oct 1, 2020 | clinicaltrials |
| NCT00536978 | Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03232619 | CD19-CART Treatment for ALL | completed | Phase 1 / Phase 2 | 4 | Bioray LaboratoriesINDUSTRY | 1 | Sep 22, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02928523 | PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients(ODYSSEE) | completed | Phase 1 / Phase 2 | 20 | MaaT PharmaINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT01274351 | Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03820908 | Bisantrene for Relapsed /Refractory AML | completed | Phase 2 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01830361 | Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML(MIDOKIT) | completed | Phase 2 | 18 | Technische Universität DresdenOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT01235572 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | completed | Phase 2 | 200 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00274820 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder | completed | Phase 2 | 15 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01866839 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | completed | Phase 1 / Phase 2 | 41 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 21, 2020 | clinicaltrials |
| NCT01317940 | Nutrition and Body Composition in Acute Lymphoblastic Leukemia | completed | Phase 2 | 76 | Children's Hospital Los AngelesOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03593304 | Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients | completed | Phase 2 / Phase 3 | 40 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT02405338 | DC Vaccination for Post-remission Therapy in AML | completed | Phase 1 / Phase 2 | 20 | Medigene AGINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT01269385 | Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 22 | Mayo ClinicOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT02689141 | Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) | completed | Phase 2 | 66 | German CLL Study GroupOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT01477606 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | completed | Phase 2 | 451 | University of UlmOTHER | 2 | Jun 4, 2020 | clinicaltrials |
| NCT02472691 | Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT(AZALENA) | completed | Phase 2 | 50 | Heinrich-Heine University, DuesseldorfOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02481297 | Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | completed | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT01109069 | Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 2 | 199 | Pharmacyclics LLC.INDUSTRY | 1 | May 27, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT01370213 | NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases | completed | Phase 2 | 25 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT01490723 | Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | completed | Phase 2 | 70 | medac GmbHINDUSTRY | 6 | May 4, 2020 | clinicaltrials |
| NCT00553202 | Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | 158 | Children's Oncology GroupNETWORK | 2 | Apr 16, 2020 | clinicaltrials |
| NCT01252667 | Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 44 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01786343 | Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | completed | Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT02912676 | Thiopurine EnhAnced Maintenance Therapy(TEAM) | completed | Phase 1 / Phase 2 | 30 | Kjeld SchmiegelowOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT00566696 | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | completed | Phase 2 | 73 | St. Jude Children's Research HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00562328 | Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Mayo ClinicOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00857389 | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT00049075 | Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 128 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03170895 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | completed | Phase 2 | 5 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03622541 | Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01010217 | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | completed | Phase 2 | 176 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT01626495 | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma(Pedi CART19) | completed | Phase 1 / Phase 2 | 73 | University of PennsylvaniaOTHER | 1 | Mar 23, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Nov 4, 2020source: clinicaltrials